Personalized medicine in metastatic colorectal cancer treated with anti-epidermal growth factor receptor agents: A future opportunity?

Asia-Pacific Journal of Clinical Oncology

Volumn 10, Issue SUPPL.1, 2014, Pages 2-10

  Tejpar, Sabine ^a   Piessevaux, Hubert ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Hôpital Saint Luc   (Belgium)

Author keywords

Colorectal neoplasm; Individualized medicine; Molecular targeted therapy; Mutation genetic; Neoplasm therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; BIOLOGICAL PRODUCT; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MOLECULAR MARKER;

CANCER CHEMOTHERAPY; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; DRUG RESPONSE; HUMAN; METASTATIC COLORECTAL CANCER; MOLECULAR BIOLOGY; PERSONALIZED MEDICINE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR GROWTH;

COLORECTAL NEOPLASM; INDIVIDUALIZED MEDICINE; MOLECULAR-TARGETED THERAPY; MUTATION/GENETIC; NEOPLASM/THERAPY;

COLORECTAL NEOPLASMS; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84893641102     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/ajco.12176     Document Type: Review

References (38)

1. Benedix F, Kube R, Meyer F etal. Comparison of 17, 641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum 2010; 53: 57-64.
2. Meguid RA, Slidell MB, Wolfgang CL, Chang DC, Ahuja N. Is there a difference in survival between right- versus left-sided colon cancers? Ann Surg Oncol 2008; 15: 2388-2394.
3. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 2009; 361: 2449-2460.
4. Budinska E, Popovici V, Tejpar S etal. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J Pathol 2013; 231: 63-76.
5. Cunningham D, Humblet Y, Siena S etal. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
6. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208.
7. Lievre A, Bachet JB, Le Corre D etal. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992-3995.
8. Van Cutsem E, Kohne CH, Hitre E etal. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
9. Karapetis CS, Khambata-Ford S, Jonker DJ etal. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765.
10. Jonker DJ, O'Callaghan CJ, Karapetis CS etal. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040-2048.
11. Amado RG, Wolf M, Peeters M etal. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634.
12. De Roock W, Claes B, Bernasconi D etal. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753-762.
13. Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 2012; 30: 3570-3577.
14. Baker JB, Dutta D, Watson D etal. Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer. Br J Cancer 2011; 104: 488-495.
15. Pentheroudakis G, Kotoula V, De Roock W etal. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF: PIK3CA genotypes. BMC Cancer 2013; 13: 49.
16. De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011; 12: 594-603.
17. Yang ZY, Wu XY, Huang YF etal. Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis. Int J Cancer 2013; 133: 1914-1925.
18. Martin V, Landi L, Molinari F etal. HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. Br J Cancer 2013; 108: 668-675.
19. Islam R, Chyou PH, Burmester JK. Modeling efficacy of bevacizumab treatment for metastatic colon cancer. J Cancer 2013; 4: 330-335.
20. Nishino M, Jagannathan JP, Krajewski KM etal. Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am J Roentgenol 2012; 198: 737-745.
21. Laubender RP, Schlichting M, Sartorius U etal. Evaluating the agreement between the empirical volumes of tumor lesions and the estimated volumes of tumor lesions based on the longest diameter. ASCO Meeting Abstracts 2012; 30: 635.
22. Mansmann UR, Sartorius U, Laubender RP, Giessen CA, Esser R, Heinemann V. Deepness of response: a quantitative analysis of its impact on post-progression survival time after first-line treatment in patients with mCRC. ASCO Meeting Abstracts 2013; 31: 427.
23. Suzuki C, Blomqvist L, Sundin A etal. The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy. Ann Oncol 2012; 23: 948-954.
24. Piessevaux H, Buyse M, De Roock W etal. Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial). Ann Oncol 2009; 20: 1375-1382.
25. Stintzing S, Kapaun C, Laubender RP etal. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. Int J Cancer 2013; 132: 236-245.
26. Van Cutsem E, Kohne CH, Lang I etal. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-2019.
27. Bokemeyer C, Bondarenko I, Hartmann JT etal. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011; 22: 1535-1546.
28. Maughan TS, Adams RA, Smith CG etal. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377: 2103-2114.
29. Mansmann UR, Laubender RP, Giessen CA, Sartorius U, Heinemann V. Validating the prognostic relevance of initial change in tumor size using a series of therapeutic regimens for patients with metastatic colorectal cancer (mCRC). ASCO Meeting Abstracts 2012; 30: 580.
30. Piessevaux H, Van Cutsem E, Bokemeyer C, Schlichting M, Heeger S, Tejpar S. Early tumor shrinkage and long-term outcome in metastatic colorectal cancer (mCRC): assessment of predictive utility across treatment arms in the CRYSTAL and OPUS studies. ASCO Meeting Abstracts 2011; 29: 3572.
31. Misale S, Yaeger R, Hobor S etal. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486: 532-536.
32. Diaz LA Jr, Williams RT, Wu J etal. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012; 486: 537-540.
33. Basik M, Aguilar-Mahecha A, Rousseau C etal. Biopsies: next-generation biospecimens for tailoring therapy. Nat Rev Clin Oncol 2013; 10: 437-450.
34. Wilson TR, Fridlyand J, Yan Y etal. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012; 487: 505-509.
35. Heinemann V, Fischer von Weikersthal L, Decker T etal. Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). ASCO Meeting Abstracts 2013; 31: LBA3506.
36. Mansmann UR, Sartorius U, Laubender RP, Giessen CA, Esser R, Heinemann V. Quantitative analysis of the impact of deepness of response on post-progression survival time following first-line treatment in patients with mCRC. ASCO Meeting Abstracts 2013; 31: 3630.
37. Clinicaltrials.gov. Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC) (VISNU-2) (NCT01640444). [Cited 5 Jul 2013.] Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT01640444?term=bevacizumab+cetuximab&rank=1.
38. Mansmann UR, Sartorius U, Laubender RP, Giessen CA, Esser R, Heinemann V. Deepness of response: a quantitative analysis of its impact on post-progression survival time after first-line treatment in patients with mCRC. ASCO Meeting Abstracts 2013; 31: 427.